|Day Low/High||6.28 / 6.64|
|52 Wk Low/High||4.31 / 16.05|
In trading on Tuesday, shares of Depomed Inc crossed above their 200 day moving average of $7.85, changing hands as high as $7.96 per share. Depomed Inc shares are currently trading up about 1.8% on the day.
Investors in Depomed Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new April 20th contracts and identified one put and one call contract of particular interest.
A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.
In trading on Thursday, shares of Depomed Inc crossed above their 200 day moving average of $8.57, changing hands as high as $8.58 per share. Depomed Inc shares are currently trading up about 2.8% on the day.
Closing Triggers Upfront $10 Million Payment to Depomed
In recent trading, shares of Depomed Inc have crossed above the average analyst 12-month target price of $8.14, changing hands for $8.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
These names are showing bullish or bearish reversal patterns that occurred over the past week.
TheStreet recounts the successes and failures of the biggest names in the activism game.
Investors in Depomed Inc saw new options begin trading this week, for the June 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
25 Year Pharmaceutical and Biotechnology Industry Executive Joins Senior Management Team
Glancy Prongay & Murray LLP ("GPM") reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the...
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Depomed, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.